Date:5/23/2012

country ($m), 2006–10 20Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 22Figure 5: Canada pharmaceuticals market value: $ million, 2006–10 25Figure 6: Canada pharmaceuticals market segmentation: % share, by value, 2010 26Figure 7: Canada pharmaceuticals market share: % share, by value, 2010 27Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2010 28Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2010 29Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2010 31Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010 33Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010 35Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010 37Figure 14: AstraZeneca PLC: revenues & profitability 42Figure 15: AstraZeneca PLC: assets & liabilities 42Figure 16: Johnson & Johnson: revenues & profitability 45Figure 17: Johnson & Johnson: assets & liabilities 46Figure 18: Pfizer Inc.: revenues & profitability 49Figure 19: Pfizer Inc.: assets & liabilities 49Figure 20: Canada pharmaceuticals market value forecast: $ million, 2010–15 50Figure 21: France pharmaceuticals market value: $ million, 2006–10 54Figure 22: France pharmaceuticals market segmentation: % share, by value, 2010 55Figure 23: France pharmaceuticals market share: % share, by value, 2010 56Figure 24: Forces driving competition in the pharmaceuticals market in France, 2010 57Figure 25: Drivers of buyer power in the pharmaceuticals market in France, 2010 58Figure 26: Drivers of supplier power in the pharmaceuticals market in France, 2010 60Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010 62Figure 28: Factors influencing the threat of substitutes in the pharmaceutic
'/>"/>

SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate